Navigation Links
Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology™
Date:5/10/2011

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform, announced today a three year strategic collaboration with MedImmune LLC, the global biologics business of AstraZeneca. The agreement provides MedImmune with non-exclusive access to Pfenex Expression Technology and scientific resources for the development of bioprocesses for human therapeutic proteins and vaccines.

Pfenex Inc. will engineer production strains and develop early production processes for MedImmune's proprietary molecules. A Joint Steering Committee will be established to oversee the collaboration and facilitate the decision-making process. This collaboration provides MedImmune with access to an industry-leading expression platform and process development team that will enable preclinical and clinical development for these molecules to progress quickly and efficiently. MedImmune will provide annual technology access fees, FTE resource funding and will also have pre-agreed commercial license terms.

"This partnership with MedImmune will facilitate speed and reliability in the development of protein therapeutics and vaccines to serve unmet medical needs," said Dr. Bertrand Liang, CEO of Pfenex Inc. "Integrating our efforts early will allow for the rapid progression of early stage candidate molecules through discovery and development."

"We are very excited to initiate this collaboration with Pfenex" said Dr. Gail Wasserman, Senior Vice President of Biopharmaceutical Development at MedImmune. "Their scientific approach to strain development and protein expression is robust and aligned with the way we work at MedImmune.  Working collaboratively with Pfenex by harnessing their novel platform will play an important role in helping accelerate some of our early pipeline programs."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals.  For more information please visit www.pfenex.com

About MedImmune, LLC

MedImmune, the global biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
2. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
3. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
4. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
5. Insmed Announces First Quarter 2011 Financial Results
6. Intercell AG Announces Q1 2011 Results and Updates on R&D Progress
7. Mindray Announces First Quarter 2011 Financial Results
8. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
9. Rosetta Genomics Announces Issuance of Additional U.S. Patent
10. Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
11. Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NORTH READING, Mass. , Dec. 7, 2016 ... Track and Trace Network for connecting the Life ... from the global marketplace, today announced that Tjoapack ... 50+ European pharmaceutical manufacturing customers comply with the ... Supply Chain Security Act (DSCSA) in 2017 and ...
(Date:12/7/2016)... 7, 2016  Varian Medical Systems (NYSE: ... announced plans to separate its Imaging Components business.  The ... distribution to Varian stockholders of common stock in Varex ... hold the Imaging Components business.  As part of the ... the end of January 2017, Varian will receive an ...
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... and financial planning services to families and business owners in the greater Dallas ... behalf of the Dallas Fallen Officer Foundation. , Established in 2009 by active ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... AlignLife clinics ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under ... presents can bring to the children of the world. , In exchange for generous ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... The study was published in the prestigious Journal of Veterinary Science & Medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and medical ... which launched October 17, 2016, features comprehensive information regarding a wide range of ... and patients can discover the latest clinical dermatology treatments for medical skin concerns ...
Breaking Medicine News(10 mins):